Novartis AG (LON:0K9E)

Market Cap	181.21B
Revenue (ttm)	40.28B
Net Income (ttm)	9.97B
Shares Out	n/a
EPS (ttm)	5.00
PE Ratio	18.18
Forward PE	14.81
Dividend	2.61 (2.06%)
Ex-Dividend Date	Mar 12, 2025

Volume	124
Average Volume	2,242
Open	126.36
Previous Close	127.01
Day's Range	125.98 - 126.53
52-Week Range	96.11 - 128.50
Beta	n/a
RSI	65.08
Earnings Date	Oct 28, 2025

About Novartis AG

Novartis AG engages in the research, development, manufacture, distribution, marketing, and sale of pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor for the treatment of symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Re...

• Industry: Pharmaceutical Preparations
• Founded: 1996
• Employees: 75,883
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0K9E

Financial Performance

In 2024, Novartis AG's revenue was $51.72 billion, an increase of 10.85% compared to the previous year's $46.66 billion. Earnings were $11.94 billion, a decrease of -19.59%.

Financial numbers in USD